Related Experiment Video
Updated: Sep 9, 2025
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
620
A case report of thyroid myofibroblastic sarcoma.
Liuxue Ma1, Huijuan Wang1, Xin Li1
1Liangzhou Hospital, Wuwei, China.
Medicine
|September 3, 2025
Summary
High-grade myofibroblastic sarcoma (HGMS) is a rare thyroid cancer. This first reported case highlights its aggressive nature, rapid progression, and metastatic potential, emphasizing the need for early diagnosis.
Area of Science:
- Oncology
- Pathology
Background:
- High-grade myofibroblastic sarcoma (HGMS) is a rare mesenchymal tumor.
- HGMS has a high recurrence and metastatic rate.
- This study reports the first case of HGMS originating from the thyroid.
Purpose of the Study:
- To report the first case of HGMS originating from the thyroid.
- To describe the clinical presentation, diagnosis, and outcome of this rare tumor.
- To emphasize the importance of early diagnosis and intervention for HGMS.
Main Methods:
- Diagnosis was based on thyroid pathology and immunohistochemical staining.
- Systemic imaging was used to detect metastases.
- Clinical evaluation was performed.
Main Results:
- Grade III myofibroblastic sarcoma (MS) was diagnosed in the thyroid.
- Multiple metastases were found in the scalp, lung, bone, liver, spleen, and pancreas.
- The patient expired 28 days after admission without receiving treatment.
Conclusions:
- HGMS of the thyroid is highly invasive and metastatic.
- The tumor has a potential for rapid disease progression and poor survival outcomes.
- Early diagnosis and intervention are crucial for improving patient prognosis.
